Increased Incidence of Severe Adverse Events in Non-Small Cell Lung Cancer Patients with Previous Tuberculosis Episode Treated with PD-1 Inhibitors  

作　　者：Hui Zhang Jinfeng Yuan Yuanyuan Xu Mengjie Yang Jialin Lyu Xinjie Yang Shuyan Sheng Zhe Qian Qunhui Wang Yu Pang Ying Hu 

机构地区：[1]Department of Medical Oncology,Beijing Chest Hospital,Capital Medical University&Beijing Tuberculosis and Thoracic Tumor Research Institute,Beijing 101149,China [2]Department of Bacteriology and Immunology,Beijing Key Laboratory on Drug-Resistant Tuberculosis Research,Beijing Chest Hospital,Capital Medical University/Beijing Tuberculosis&Thoracic Tumor Research Institute,Beijing 101149,China [3]Chinese Center for Disease Control and Prevention,Beijing 102206,China

出　　处：《Biomedical and Environmental Sciences》2024年第7期785-789,共5页生物医学与环境科学（英文版）

基　　金：supported by the Beijing Hospitals Authority Clinical Medicine Development of Special Funding(ZYLX202122);Beijing Key Clinical Specialty Project(20201214);Tongzhou Lianggao Talents Project(No.YHLJ202005);Beijing Nova Program(20220484169&20230484295).

摘　　要：Lung cancer is the top cause of cancer deaths globally.Advances in immune checkpoint inhibitors(ICIs)have transformed cancer treatment,but their use in lung cancer has led to more side effects.This study examined if past pulmonary tuberculosis(TB)affects ICIs’effectiveness and safety in lung cancer treatment.We reviewed lung cancer patients treated with ICIs at Beijing Chest Hospital from January 2019 to August 2022.

关 键 词：LUNG LUNG Cancer 

分 类 号：R734.2[医药卫生—肿瘤]